GLSHQ (Gelesis Holdings) Cash Conversion Cycle: -402.81 (As of Jun. 2023)


What is Gelesis Holdings Cash Conversion Cycle?

Gelesis Holdings GLSHQ -99.00% Cash Conversion Cycle is -402.81 as of Jun. 2023.

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Gelesis Holdings's Days Sales Outstanding for the three months ended in Jun. 2023 was 85.32.
Gelesis Holdings's Days Inventory for the three months ended in Jun. 2023 was 1065.41.
Gelesis Holdings's Days Payable for the three months ended in Jun. 2023 was 1553.54.
Therefore, Gelesis Holdings's Cash Conversion Cycle (CCC) for the three months ended in Jun. 2023 was -402.81.

Gelesis Holdings  (OTCPK:GLSHQ) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.

Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.

Gelesis Holdings Cash Conversion Cycle Related Terms

Gelesis Holdings Cash Conversion Cycle Historical Data

* Premium members only.

The historical data trend for Gelesis Holdings's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gelesis Holdings Cash Conversion Cycle Chart

Gelesis Holdings Annual Data
Trend Dec21 Dec22
Cash Conversion Cycle
149.52 54.77

Gelesis Holdings Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.67 103.87 77.07 93.57 -402.81

GLSHQ vs RBSH, PPCB, RGMP: Cash Conversion Cycle Comparison

For the Biotechnology subindustry, Gelesis Holdings's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gelesis Holdings Cash Conversion Cycle vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gelesis Holdings's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Gelesis Holdings's Cash Conversion Cycle falls into.


Gelesis Holdings Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Gelesis Holdings's Cash Conversion Cycle for the fiscal year that ended in Dec. 2022 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=13.91+134.88-94.02
=54.77

Gelesis Holdings's Cash Conversion Cycle for the quarter that ended in Jun. 2023 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=85.32+1065.41-1553.54
=-402.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash Conversion Cycle →
What does a Cash Conversion Cycle of -402.81 mean?
Gelesis Holdings (GLSHQ) has a Cash Conversion Cycle of -402.81 as of Jun. 2023. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Gelesis Holdings and its competitors.
Is Gelesis Holdings' Cash Conversion Cycle too high?
Gelesis Holdings' current Cash Conversion Cycle is -402.81.
How does Gelesis Holdings' Cash Conversion Cycle compare to RBSH and PPCB?
Gelesis Holdings' Cash Conversion Cycle of -402.81 can be compared against companies in the Biotechnology industry. The industry median Cash Conversion Cycle is 103.08. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Biotechnology company?
The median Cash Conversion Cycle among Biotechnology companies is 103.08, based on 871 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Gelesis Holdings and its competitors. For the Biotechnology industry, the median Cash Conversion Cycle is 103.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gelesis Holdings's current Cash Conversion Cycle is -402.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gelesis Holdings stock overvalued right now?
Gelesis Holdings (GLSHQ) has a current Cash Conversion Cycle of -402.81. The current Cash Conversion Cycle is -402.81. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Gelesis Holdings (GLSHQ), the current Cash Conversion Cycle is -402.81 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gelesis Holdings Business Description

Address 501 Boylston Street, Suite 6102, Boston, MA, USA, 02116
Gelesis Holdings Inc is a biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.